Business UpdateOct 6, 2026, 09:16 AM
Ascendis Pharma to Present Long-Term Data on Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
AI Summary
Ascendis Pharma A/S announced it will present new clinical data for its hypoparathyroidism and achondroplasia programs at the American Society for Bone & Mineral Research (ASBMR) 2026 meeting. Key presentations include long-term data on TransCon® PTH (palopegteriparatide) demonstrating normalization of bone mass over five years in hypoparathyroidism patients. The company will also share updates on TransCon CNP (navepegritide) for achondroplasia, including data on growth and physical functioning in children. Ascendis highlighted the potential of its TransCon-based therapies to improve patient health and quality of life.
Key Highlights
- Ascendis Pharma to present long-term data on TransCon® PTH (palopegteriparatide) for hypoparathyroidism at ASBMR 2026.
- Oral presentation on October 11th will showcase 5-year skeletal data from PaTH Forward and PaTHway trials.
- Poster presentations will cover quality of life impacts of palopegteriparatide in hypoparathyroidism.
- Updates on TransCon CNP (navepegritide) for achondroplasia will be presented, including data from the ApproaCH trial extension.
- Late-breaking poster on October 11th will present 78-week results of navepegritide combined with lonapegsomatropin in the COACH trial.
- TransCon CNP (YORVIPATH®) is approved for adults with hypoparathyroidism and TransCon CNP (YUVIWEL®) is approved for children with achondroplasia.
Price Impact
More from ASND